Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 24, 2011 Brian Orelli	It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors.
The Motley Fool September 20, 2011 Brian Orelli	Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell?
The Motley Fool February 18, 2010 Brian Orelli	Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues.
The Motley Fool January 6, 2010 Brian Orelli	Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data.
The Motley Fool October 17, 2008 Brian Orelli	Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
The Motley Fool November 29, 2010 Brian Orelli	Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily.
The Motley Fool May 24, 2011 Brian Orelli	J&J Approved, but Needs Help From a Friend The HIV combo product is the key.
The Motley Fool July 17, 2009 Brian Orelli	Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson.
The Motley Fool August 9, 2011 Brian Orelli	Some Potential Good News in Biotech The FDA should approve Gilead's Btripla.
The Motley Fool January 27, 2010 Brian Orelli	The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs.
The Motley Fool July 27, 2011 Brian Orelli	Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain.
The Motley Fool April 16, 2009 Brian Orelli	2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing.
The Motley Fool October 20, 2010 Brian Orelli	What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back.
The Motley Fool July 21, 2010 Brian Orelli	15% Revenue Growth Is Good for Pfizer, but Not Gilead Gilead needs to reaccelerate growth.
The Motley Fool December 31, 2007 Brian Lawler	Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
The Motley Fool December 21, 2004 Brian Gorman	Bristol-Myers, Gilead Team Up The drugmakers' alliance will benefit both the companies and HIV patients.
The Motley Fool June 28, 2011 Brian Orelli	HIV Drug Partnership Gets a Boost Gilead and Johnson & Johnson hook up on a pair of new combo treatments.
The Motley Fool October 16, 2007 Brian Orelli	Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note.
The Motley Fool April 1, 2011 Brian Orelli	Abbott: Battle Lost, War Won A jury ordered Abbott to pay GlaxoSmithKline $3.5 million. It could have been a lot worse.
The Motley Fool November 27, 2009 Brian Orelli	A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence.
The Motley Fool February 27, 2007 Brian Lawler	Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors.
The Motley Fool April 22, 2009 Brian Orelli	Better Than Recession-Proof The whole health-care industry may not be recession-proof, but Gilead has shown that the right combination of drugs can lead to stellar returns -- even in a down economy.
The Motley Fool July 22, 2009 Brian Orelli	Grab Hold of This Growth Double-digit growth just keeps coming for Gilead Sciences.
The Motley Fool April 24, 2007 Brian Lawler	Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes.
The Motley Fool January 27, 2011 Brian Orelli	Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade.
The Motley Fool October 21, 2009 Brian Orelli	Double-Digit Growth in a Recession The strong double-digit growth at Gilead shouldn't be much of a surprise; HIV patients need their medication even in a recession.
The Motley Fool July 7, 2011 Brian Orelli	J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo.
The Motley Fool October 7, 2011 Brian Orelli	A Little Help, Please Gilead pumps up the pipeline.
The Motley Fool September 29, 2011 Brian Orelli	Are HIV Drugmakers Doomed? Generics are a bigger threat than Sangamo for now.
The Motley Fool July 21, 2006 Brian Lawler	Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet.
BusinessWeek April 25, 2005 Sarah Lacy	BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche
BusinessWeek September 2, 2010 Simeon Bennett	David Margolis' Fight to End AIDS The North Carolina professor is relying on Zolinza, a rarely used Merck cancer drug, to stamp out AIDS.
The Motley Fool April 3, 2009 Brian Orelli	Gilead: Helping Investors Cope With the Market Diversifying seems to be paying off for the drugmaker.
The Motley Fool September 25, 2007 Brian Orelli	Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note.
The Motley Fool January 30, 2008 Brian Lawler	The Competition Bites Trimeris Rivals lead to lower sales of the small specialty pharmaceutical's only marketed drug.
Pharmaceutical Executive September 1, 2010	Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days?
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
The Motley Fool December 12, 2007 Brian Orelli	What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010.
The Motley Fool August 16, 2006 S.J. Caplan	Abbott Labs' Latest Leaps Generating increased goodwill while potentially expanding its HIV drug market, together with marking progress in its new vascular stent business, proved to be a potent formula for lifting Abbott's shares early this week. Investors, take note.
Bio-IT World Jul/Aug 2006	News Blast Health Solutions... Rna Interference... HIV Triple Combo...
The Motley Fool June 19, 2009 Brian Orelli	Comparative Medicine Could Sink Your Stocks The government's plan will have a very unpredictable effect on companies.
The Motley Fool April 3, 2008 Brian Lawler	A Punch to Gilead's Competition A rival compound's bad data signals a better future for Gilead's lead drugs.
The Motley Fool April 26, 2011 Brian Orelli	There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost.
The Motley Fool January 28, 2009 Brian Orelli	Worth Every Penny People still need to take their antiviral medication even if the purse strings are tight, and that fact has led Gilead Sciences to putting together another great quarter.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool December 16, 2009 Brian Orelli	Gilead's Phase 3 Train Wreck Gilead Sciences' darusentan looked so promising.
AskMen.com Dave Golokhov	Truvada With more and more studies finding successful AIDS prevention, it looks like we're getting closer to finding a cure.